–
Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm’s biggest bet of 2014.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
One week after Allergan agreed to sell itself to rival Actavis Plc., Ackman wrote in his quarterly investment letter that his Pershing Square Capital Management, the Botox-maker’s biggest investor, still owns 26.6 million shares.
At the end of the third quarter Ackman’s $18 billion fund owned 28.87 million Allergan shares, a regulatory filing showed.
While this isn’t the deal the activist investor originally wanted – he had been pushing since April for rival Valeant buy Allergan – it will be lucrative all the same.
“If we hold the shares until transaction closure, we will receive $3.4 billion in cash and 9.81 million shares of Actavis worth $2.6 billion at current value, ” the letter said.
Currently Pershing Square’s stake is worth $5.64 billion and the stock was trading at a $15.70 discount to the transaction value, which translates into about a 19 percent annualized return assuming the deal closes next April.
Ackman’s firm is having one of its best years ever with a 35 percent gain for the year through the end of October. The average hedge fund has gained only 2 percent and the broader S&P 500 index has gained about 13 percent.
The battle for Allergan has captivated Wall Street for months, with Pershing Square waging court battles and finally winning a special meeting where it planned to replace many Allergan directors. Speculation has mounted recently over what Ackman planned to do with his holding, especially after he announced a stake in animal health company Zoetis Inc two weeks ago.
Sounding a conciliatory note, Ackman said he now supports the Actavis deal and said his team had been impressed with Actavis Chief Executive Officer Brent Saunders and his business plan for the combined company after a recent meeting.
In terms of other investments, Ackman said he still likes his short bet against Herbalife Ltd, which he disclosed publicly for the first time two years ago, and said it paid off well during the third quarter when it added 3.2 percent to the fund’s performance.
He also said he still likes the investment in mortgage companies Fannie Mae and Freddie Mac but cautioned that litigation will likely drag on for some time and that he has committed about 3 percent of the firm’s capital to the bets.
